Sign in
Enrolling by invitationNo phase

Long-term follow-up of AAVAnc80-antiVEGF gene therapy in vestibular schwannoma

Follows adults with vestibular schwannoma who earlier received AAVAnc80-antiVEGF gene therapy in the inner ear.

Key facts

Who runs it
Eli Lilly and Company
Where
Dallas, United StatesSee the site
Trial code
Registry title
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
Status
Enrolling by invitation
People taking part
100 people, planned
Started
2 Mar 2026
Expected to end
Apr 2040
Type of study
Observational
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with vestibular schwannoma who already received AAVAnc80-antiVEGF gene therapy into the inner ear (cochlea) in an earlier clinical trial. This study follows them over the long term.

Age
18 Years and older
Sex
All
Disease stage
Vestibular schwannoma, a non-cancerous tumour on the nerve between the ear and the brain.
Earlier treatment
Must have received AAVAnc80-antiVEGF into the cochlea in an earlier interventional clinical trial.

Main reasons for not taking part

  • Any condition that would stop the person from completing the follow-up exams
  • Any condition that the study doctor thinks makes the person unfit for the study

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • -Individual with vestibular schwannoma who received an intracochlear administration of
  • AAVAnc80-antiVEGF in an interventional clinical trial
  • -Participant willingness to comply with all study requirements as evidenced by successful completion of the informed consent process

Who cannot take part

  • -Any condition that would not allow the potential participant to complete follow-up examinations during the course of the study and/or, in the opinion of the Investigator, makes the potential participant unsuitable for the study

Where in United States

  • University of Texas, SouthwesternDallas, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This multi-center, observational, post-intervention LTFU study will monitor for safety and efficacy of AAVAnc80- antiVEGF in individuals with vestibular schwannoma who have previously received an intracochlear administration of AAVAnc80-antiVEGF in an interventional clinical trial

The group in the trial

  • Study Participants

    Individuals with vestibular schwannoma who received an intracochlear administration of AAVAnc80-antiVEGF in an interventional clinical trial.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Evaluation of the Long Term Safety and Efficacy of AAVAnc80-antiVEGF Gene Therapy in Individuals With Vestibular Schwannoma
Plain-language title
Long-term follow-up of AAVAnc80-antiVEGF gene therapy in vestibular schwannomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
4 November 2026